Proposed Local Coverage Determination (LCD) - MolDX: Signatera™ and MinimalResidual Disease Testing for Colorectal Cancer (DL38290)

Nov 20

Medicare Coverage of Innovative Technology & Definition of “Reasonable & Necessary”